On July 23, according to the “Takeda China” WeChat account, Takeda's innovative drug in the field of neuroscience was officially approved by the China Drug Administration to treat patients with narcolepsy type 1 in adolescents and adults aged 16 and above. As a result, China became the first approved market for opreton tablets in the world.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.